<i>Artemisia scoparia</i> promotes adipogenesis in the absence of adipogenic effectors

Harvey, Innocence; Stephens, Jacqueline M.

doi:10.1002/oby.23199

Cited by 5 publications

(4 citation statements)

References 47 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study has revealed that SCOPA can promote adipogenesis in the absence of 3-isobutyl-1-methylxanthine (MIX), a key component in the classic adipocyte differentiation cocktail, and SCOPA significantly induces the expression of several PPARg target genes, also regulated by MIX, that enhance lipid accumulation during adipogenesis. These data suggest that SCOPA's adipogenic effects are partially mediated by increased PPARg activity (52). Another research group investigating individual compounds isolated from a different SCOPA extract reported that 4 of the 19 compounds tested significantly inhibited lipid accumulation in 3T3-L1 cells during differentiation, while other compounds enhanced adipocyte development (53).…”

Section: Effects Of a Scoparia On Determinants Of Metabolic Health Me...mentioning

confidence: 99%

Artemisia scoparia and Metabolic Health: Untapped Potential of an Ancient Remedy for Modern Use

et al. 2022

Self Cite

View full text Add to dashboard Cite

Botanicals have a long history of medicinal use for a multitude of ailments, and many modern pharmaceuticals were originally isolated from plants or derived from phytochemicals. Among these, artemisinin, first isolated from Artemisia annua, is the foundation for standard anti-malarial therapies. Plants of the genus Artemisia are among the most common herbal remedies across Asia and Central Europe. The species Artemisia scoparia (SCOPA) is widely used in traditional folk medicine for various liver diseases and inflammatory conditions, as well as for infections, fever, pain, cancer, and diabetes. Modern in vivo and in vitro studies have now investigated SCOPA’s effects on these pathologies and its ability to mitigate hepatotoxicity, oxidative stress, obesity, diabetes, and other disease states. This review focuses on the effects of SCOPA that are particularly relevant to metabolic health. Indeed, in recent years, an ethanolic extract of SCOPA has been shown to enhance differentiation of cultured adipocytes and to share some properties of thiazolidinediones (TZDs), a class of insulin-sensitizing agonists of the adipogenic transcription factor PPARγ. In a mouse model of diet-induced obesity, SCOPA diet supplementation lowered fasting insulin and glucose levels, while inducing metabolically favorable changes in adipose tissue and liver. These observations are consistent with many lines of evidence from various tissues and cell types known to contribute to metabolic homeostasis, including immune cells, hepatocytes, and pancreatic beta-cells. Compounds belonging to several classes of phytochemicals have been implicated in these effects, and we provide an overview of these bioactives. The ongoing global epidemics of obesity and metabolic disease clearly require novel therapeutic approaches. While the mechanisms involved in SCOPA’s effects on metabolic, anti-inflammatory, and oxidative stress pathways are not fully characterized, current data support further investigation of this plant and its bioactives as potential therapeutic agents in obesity-related metabolic dysfunction and many other conditions.

show abstract

Section: Effects Of a Scoparia On Determinants Of Metabolic Health Me...mentioning

confidence: 99%

Artemisia scoparia and Metabolic Health: Untapped Potential of an Ancient Remedy for Modern Use

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is our view that botanicals are an underappreciated resource for potential pharmaceutical advancements. We have previously reported that SCO and ROSI display some common activities pertaining to PPARγ regulation and the promotion of adipogenesis; however, they also have distinct properties, suggesting that SCO may provide a safer alternative to ROSI in the treatment of metabolic dysfunction [55,56]. Here, we show that ROSI and SCO also differ in their effects on GC-induced lipolysis and on PDE protein levels (Figure 6), providing further support for SCO's unique effects on metabolic responses in adipocytes that are distinct from ROSI.…”

Section: (A)mentioning

confidence: 99%

An Artemisia scoparia extract attenuates glucocorticoid‐induced lipolysis in adipocytes

Harvey

Stephens

2023

Obesity

Self Cite

View full text Add to dashboard Cite

Objective: Prescription glucocorticoid (GC) use is widespread across developed countries for the treatment of several inflammatory conditions. Elevated GCs are known to promote lipolysis and metabolic disorders. An extract of Artemisia scoparia (SCO) has been shown to reduce lipolysis and promote metabolic health but has not been investigated in the context of excess GCs. Our aim was to examine the effects of SCO on GC-induced lipolysis.Methods: Mature adipocytes were pretreated with vehicle or SCO, then exposed to either the synthetic GC dexamethasone (DEX) or tumor necrosis factor alpha (TNFα).Medium was collected and assayed for glycerol and fatty acids as measures of lipolysis. The expression of several lipolytic genes and proteins was assessed, and the involvement of glucocorticoid receptor (GR) in SCO's effects was also interrogated.Results: SCO significantly attenuated DEX-induced lipolysis but did not interfere with DEX-mediated changes in inflammatory gene profiles in adipocytes. SCO treatment resulted in significant reductions in monomeric phosphodiesterase (PDE) protein levels while elevating PDE multimeric complex formation, but other canonical lipolytic mediators were unaltered. SCO attenuated lipolysis even when GR expression was significantly knocked down. Finally, it was demonstrated that SCO was distinct from rosiglitazone in its antilipolytic effects.Conclusions: SCO attenuates GC-induced lipolysis independently of GR activity.Future studies are needed to elucidate underlying mechanisms.

show abstract

“…On its activation, PPAR-γ pancreatic insulin secretion is found to decrease and reduces fatty acids in blood. Most of the effects of TZDs are driven by adipocyte differentiation, which increases glucose transporters (GLUT4) and induces lipogenic genes (AP2 and CD36) [ 127 ]. Reportedly, some derivatives of TZD, MSDC-0160 and MSDC-0602 were observed to cause anti-diabetic effects via PPAR-γ, mitochondrial membranes and the pyruvate carriers (MCP1 and MCP2) [ 6 , 128 ].…”

Section: Ppar-γ Agonists In Various Diseasesmentioning

confidence: 99%

PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer

Ballav

Biswas

Sahu

et al. 2022

Cells

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptor-γ (PPAR-γ) has emerged as one of the most extensively studied transcription factors since its discovery in 1990, highlighting its importance in the etiology and treatment of numerous diseases involving various types of cancer, type 2 diabetes mellitus, autoimmune, dermatological and cardiovascular disorders. Ligands are regarded as the key determinant for the tissue-specific activation of PPAR-γ. However, the mechanism governing this process is merely a contradictory debate which is yet to be systematically researched. Either these receptors get weakly activated by endogenous or natural ligands or leads to a direct over-activation process by synthetic ligands, serving as complete full agonists. Therefore, fine-tuning on the action of PPAR-γ and more subtle modulation can be a rewarding approach which might open new avenues for the treatment of several diseases. In the recent era, researchers have sought to develop safer partial PPAR-γ agonists in order to dodge the toxicity induced by full agonists, akin to a balanced activation. With a particular reference to cancer, this review concentrates on the therapeutic role of partial agonists, especially in cancer treatment. Additionally, a timely examination of their efficacy on various other disease-fate decisions has been also discussed.

show abstract

Artemisia scoparia promotes adipogenesis in the absence of adipogenic effectors

Abstract: O b e s i t y B i o l o g y a n d I n t e g r a t e d P h y s i o l o g y

Cited by 5 publications

References 47 publications

Artemisia scoparia and Metabolic Health: Untapped Potential of an Ancient Remedy for Modern Use

Artemisia scoparia and Metabolic Health: Untapped Potential of an Ancient Remedy for Modern Use

An Artemisia scoparia extract attenuates glucocorticoid‐induced lipolysis in adipocytes

PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer

Contact Info

Product

Resources

About